All posts by imreal

Maxx Orthopedics announces Farzin Khaghani as Chief Commercial Officer


Mr. Farzin Khaghani

“We are thrilled to have a forward-thinking leader with Farzin’s industry expertise, skill for steering cross-functional teams and passion for excellence across the company.”

Maxx Orthopedics, Inc., a rapidly expanding global orthopedics device company, announced today that Farzin Khaghani has joined the organization in the newly created role of Chief Commercial Officer. This will better position Maxx Orthopedics to improve and drive its strategic initiatives within the US market. Mr. Khaghani will be responsible for mobilizing the full commercial power of the organization, from sales and marketing to profit and revenue generation.

Mr. Khaghani brings over 25 years of experience in the medical device industry as an accomplished and growth-focused executive with a solid history of commercializing multiple disruptive products within the healthcare industry. He has held various roles as VP of Sales, VP of Marketing and President at both private and public medical device companies including Conformis, NextStep Arthropedix and Johnson & Johnson.

Ashesh Shah, CEO of Maxx Orthopedics, expresses “We are thrilled to have a forward-thinking leader with Farzin’s industry expertise, skill for steering cross-functional teams and passion for excellence across the company. He will be an extremely valuable addition in helping propel our business forward as we focus on advancing our growth strategy in the US.”

Mr. Khaghani holds a BS in biology and mathematics from Cornell University, a MS in mechanical engineering from Boston University, an Executive MBA from Suffolk University’s Sawyer School of Management, and in 2021 completed his first year of law school. He also serves as a member of the External Advisory Board for the Graduate School of Biomedical Science and Engineering at the University of Maine.

About Maxx Orthopedics

Maxx Orthopedics is the manufacturer of the Freedom Knee® System, Libertas® Total Hip System and Quick Recovery Solutions (QRS®). The company develops and markets innovative orthopedic medical devices worldwide with a focus on providing state-of-the-art implants and related solutions that best restore patient mobility while accommodating lifestyle, anatomical and economic needs. Find out more at http://www.maxxortho.com.

Share article on social media or email:

The Costello Law Firm Website Now in Full Compliance with Americans with Disabilities Act


We’re delighted to work with accessiBe to make our website fully accessible and user-friendly for all of our clients including those with disabilities covered under the ADA, said Christopher Costello, managing partner of the Costello Law Firm.

TheCostello Law Firm (Costello), a civil law firm specializing in personal injury law, worker’s compensation and healthcare provider law, today announced a strategic partnership with AI technology provider accessiBe to bring its website in full compliance with the Americans with Disabilities Act (ADA) and WCAG 2.1.

Today, people with disabilities currently make up roughly 20% of the total US population, leaving one in five individuals without proper access to the internet. Since all accessibility (digital and physical) is a civil right, companies and law firms like Costello need to ensure that their websites are accessible for all users

“We’re delighted to work with accessiBe to make our website fully accessible and user-friendly for all of our clients including those with disabilities covered under the ADA,” said Christopher Costello, managing partner of the Costello Law Firm. “We hope to lead by example so other law firms across the state of New Jersey and the country at large will join us in ensuring a level digital playing field for everyone seeking legal services on the Internet.”

Thanks to accessiBe’s AI technology, Costello Law Firm’s website is now fully equipped to provide the following website profile enhancements for people with disabilities:

  • Seizure Safe – clears flashes and reduces color
  • Vision Impaired – enhances website’s visuals
  • ADHD Friendly – more focus and fewer distractions
  • Cognitive Disability – assists with reading and focusing
  • Keyboard Navigations (Motor) – use website with keyboard
  • Blind Users – optimize website for screen readers


“We are committed to partnering with professionals, from web agencies to freelance developers and marketers, to equip them with the tools they need to open their websites to the disability community,” said Shir Ekerling, co-founder and CEO of accessiBe. “We are thrilled to partner with Costello to help ensure that their clients can achieve and maintain web accessibility. This includes 24-hour automatic maintenance scans of any new and updated content, along with monthly compliance audits.”

The ADA is the United States’ most important law regarding accessibility and civil rights for people with disabilities. Originally signed into law in 1990, the ADA prohibits discrimination against anyone based on ability or disability. In 2017, a clear consensus emerged that the ADA also covers the online world. Disability rights activists, legal scholars, and court rulings have agreed that websites, internet portals, and online stores need to be accessible for people with disabilities.

Today, U.S. courts apply ADA accessibility requirements to the internet, meaning websites should comply with ADA rules. Reinforcement was displayed by the Department of Justice in 2022 when it released a new guidance on implementing web accessibility standards and practices, clarifying that the ADA indeed covers web accessibility.

ADA title III-related lawsuits have skyrocketed. There were at least 11,452 federal filings in 2021, which is a 320 percent increase over a short, eight-year period. And, as of 2020, approximately 265,000 filings were sent to businesses that operated inaccessible websites.

About The Costello Law Firm

Costello Law Firm serves clients in and beyond the Burlington County area in New Jersey specializing in personal injury law, worker’s compensation and healthcare provider law. The firm’s mission is to provide its clients with the highest level of professional assistance. These are not just words, but the value that drives everyone in the firm. Costello Law Firm is dedicated to obtaining financial justice from the parties responsible for your losses and protecting you and your emotional well-being during stressful times. For more information, visit http://www.thecostellolawfirm.com.

About accessiBe

accessiBe is the market leader in AI-powered web accessibility solutions and technologies. As a web accessibility hub, accessiBe provides different solutions for testing and remediating web accessibility, as well as various professional services, to make the web inclusive and help businesses and agencies comply with web accessibility standards and regulations.

accessiBe’s full suite of web accessibility solutions enables agencies and businesses of all sizes, from solopreneur to large corporations, to take part in global inclusion efforts by making their websites available to everybody, regardless of ability.

accessiBe’s founding team has deep domain expertise in the field of web development and accessibility services and has developed the technologies in close partnership with users who have vision impairments or blindness, epilepsy, motor impairments, cognitive dysfunctions, and other disabilities. For more information, visit https://accessibe.com/

Share article on social media or email:

MCI USA Selected to Partner on NMA Annual Convention & Scientific Assembly


News Image

MCI USA’s convention division is pleased to continue its partnership with the National Medical Association, providing registration services for its Annual Convention & Scientific Assembly. NMA is the largest and oldest national organization representing African American physicians and their patients in the United States.

“MCI USA is thrilled to continue working with NMA,” said Chris Williams, SVP, Registration & Housing, MCI USA. “With our industry-leading OneSystem Plus platform, we will be able to provide next-level, fully customizable registration solutions that will give event attendees a seamless experience when registering.”

With more than 50,000 members, NMA is committed to improving the quality of health among minorities and disadvantaged people through its membership, professional development, community health education, advocacy, research, and partnerships with federal and private agencies. The NMA Annual Convention & Scientific Assembly, considered the nation’s foremost forum on medical science and African American health, brings together African American physicians and other health professionals from across the country to participate in the scholarly exchange of medical advances, discuss health policy priorities, and share experiences through networking.

For over 30 years, MCI USA’s convention division has been providing registration, housing, lead cultivation, and business intelligence solutions to events of all sizes and complexity around the world. MCI’s registration and housing services are powered by OneSystem Plus, the industry’s most complete and customizable registration and housing platform.

ABOUT MCI 

MCI is a global engagement and marketing agency. We design human-centric solutions that unleash the power of people to deliver innovation and growth for our clients. Our offering includes live & virtual events, strategic & digital communications, consulting & community solutions. We help brands, companies, associations and not-for-profits solve their challenges, bringing their people together to shape their tomorrow. MCI is an independently owned company headquartered in Geneva, Switzerland, with a global presence in 60 offices across 31 countries. http://www.wearemci.com 

MCI’s U.S. headquarters is in the Washington, D.C., area with offices in New York, Baltimore, Dallas, and Chicago. http://www.wearemci.com/en-us

Share article on social media or email:

RxBenefits Launches Patient Assistance Solutions to Curb Specialty Drug Costs for Self-Funded Plans


News Image

At RxBenefits, we leverage our negotiating power, clinical expertise, and exceptional service to do what’s right for our clients and their members.

RxBenefits, the employee benefits industry’s first technology-enabled pharmacy benefits optimizer (PBO), is proud to announce the launch of two new Patient Assistance solutions. Designed to complement RxBenefits’ comprehensive suite of pharmacy solutions, these alternative funding offerings can help reduce specialty drug costs for some patients and plans.

Specialty medications provide breakthrough – sometimes life-saving – treatments for complex, chronic, and rare diseases; however, the cost of these drugs can be prohibitive for self-funded plans. In fact, specialty drugs account for approximately half of U.S. pharmacy drug spend. When such costly drugs are required, plan sponsors are challenged with supporting members and providing a positive experience. The Patient Assistance solutions from RxBenefits address key shortcomings of current patient assistance offerings while also alleviating the financial strain for plan sponsors and patients alike.

With these solutions, patients receive their medications, even if alternative funding is unavailable or the patient doesn’t qualify for need-based assistance. The solutions can offer substantial savings opportunities in the right situations where other market alternatives fall short. These Patient Assistance solutions uphold the RxBenefits approach, ensuring members have a quality service experience while getting the medications they need based on necessary clinical oversight. In keeping with the company’s client-aligned business model, RxBenefits does not receive any fees or commissions related to these solutions.

“At RxBenefits, we leverage our negotiating power, clinical expertise, and exceptional service to do what’s right for our clients and their members,” said Wendy Barnes, CEO, RxBenefits. These Patient Assistance solutions improve clinical oversight and the member experience for alternative funding options.

“This solution set is just one piece of the specialty management puzzle,” Barnes added. “There is no single solution to managing specialty drug costs. A multi-pronged approach to address both specialty drug spend and volatility is critical to doing what’s right for patients by making specialty drugs more accessible and affordable for them and plan sponsors.”

In addition to the new Patient Assistance solutions, the RxBenefits comprehensive specialty pharmacy approach also includes:

  • Optimize 360: RxBenefits’ flagship solution handles every aspect of the pharmacy process, from initial contract negotiations to ongoing plan support and exceptional client and member service. RxBenefits’ client-aligned contracts pass 100% of scaled discounts and rebates to the plan.
  • RxBenefits Protect: A solution that delivers independent clinical expertise, oversight, and intervention to eliminate wasteful spending while protecting the health and safety of plan members. Protect programs are designed and led by independent PharmDs to ensure the plan pays for appropriate and necessary medications, and nothing more.
  • RxPharmacy Assurance: Self-funded employers face skyrocketing prescription benefit costs driven almost exclusively by specialty drug claims. RxPharmacy Assurance mitigates risk from high-cost specialty drug claims and may reduce traditional stop-loss premiums.

Patient Assistance solutions – used in tandem with RxBenefits Protect – provide two options to maximize the benefits of alternative funding while still ensuring patients receive medication quickly. Both options cut costs by tapping into available drug manufacturer assistance dollars, helping vulnerable members access medically necessary and appropriately prescribed high-cost specialty medications. As with any benefit option, Patient Assistance solutions should be evaluated on a case-by-case basis, because not every plan would benefit. RxBenefits can conduct a no-obligation, in-depth analysis for plans to account for money lost from manufacturer rebates if Patient Assistance solutions are considered.

“Self-funded plans require a comprehensive, layered approach to managing specialty spend, and the utilization of alternative funding is one more way RxBenefits helps self-funded plans save on specialty drugs,” said Mark Campbell, SVP of Clinical Solutions, RxBenefits. “We’re excited to work with our preferred providers to ensure available and appropriate savings are passed along to patients and plans.”    

To learn more about RxBenefits’ Patient Assistance solutions, visit rxbenefits.com/solutions/preferred-financial-assistance-solutions. Additional information on the company’s full suite of solutions is available at http://www.rxbenefits.com/solutions.

About RxBenefits

RxBenefits is a technology-enabled pharmacy benefits optimizer (PBO) with more than 800 pharmacy pricing, data, and clinical experts working together to deliver prescription benefit savings to employee benefit consultants and their self-insured clients. With more than 3 million members, RxBenefits brings market-leading purchasing power, independent clinical solutions, and high-touch service to its customers – ensuring that all plan sponsors, regardless of size, can provide an affordable and valuable pharmacy benefit plan to their employees. The company is headquartered in Birmingham, Ala. with a second office in Towson, Md. For more details, visit http://www.rxbenefits.com or follow the company on Facebook, Twitter, and LinkedIn.

Share article on social media or email:



Bola AI Partners with Overjet to Improve Dental Solutions with AI


News Image

Our partnership with Overjet will prove to be a win for both dental professionals and patients.

Bola Technologies, Inc. (Bola AI), a leading provider of voice-AI technology for healthcare and dental care professionals, today announced a pivotal partnership with Overjet, an industry leader in dental artificial intelligence. The union will make the best in cutting-edge AI technology available to dental offices everywhere as part of a preferred pricing package.

Bola AI’s Voice Perio system, which enables dental staff to seamlessly enter periodontal data directly into client PMS and EHR systems in real time, will complement Overjet’s platform, which analyzes dental images, quantifies detected pathology and turns X-rays into powerful patient motivators. The partnership will not only save time for busy hygienists but also lessen the burden of clinical patient documentation for additional office staff.

“Our partnership with Overjet will prove to be a win for both dental professionals and patients,” said Rushi Ganmukhi, CEO and founder of Bola AI. “In conversations with mutual customers, we have heard amazing things about what Overjet has to offer, and it is our pleasure to work with them. Our combined AI technologies perfectly complement one another and will not only deliver amazingly accurate results but also free dentists up to spend more time doing what they love best: serving the healthcare needs of their patients.”

In recent years, AI and deep learning have made incredible strides, with computer vision, language processing and speech recognition achieving near-human levels. Bola AI’s Voice Perio delivers speech accuracy at 99% and allows for variable accents and flexible phrasing while filtering out background noise and nonclinical speech. Bola AI offers the first clinical voice assistant for the dental market to utilize this new age of technology while providing unprecedented ease of use and accuracy.

“At Overjet, we are proud to be at the forefront of utilizing AI to transform dental care,” said Wardah Inam, CEO. “To that end, our mission directly aligns with that of Bola AI. We each provide complementary solutions that appeal to dentists for reasons of speed, accuracy and efficiency that all result in improved quality of care for patients.”

Overjet’s platform improves the patient experience by automatically annotating X-rays to bring color, visibility, transparency and quantification into clinical patient communication — enabling staff to communicate more confidently and effectively, resulting in better case acceptance. Guided by a patient-centric AI, Overjet’s FDA-cleared platform offers more data points in X-rays than previously possible. Overjet identifies key findings that lead to better care and patient outcomes that drive business and revenues forward.

The partnership between Bola AI and Overjet is a boost in the mission to upgrade dental offices across the country struggling with staffing issues while also providing improved infection control and patient education benefits. Their shared goal of being able to offer innovative patient exams without touching a computer is now one step closer to becoming a reality.

About Bola AI

With Bola AI, the future of speech artificial intelligence (AI) is here. By harnessing the power of advanced technologies, this platform can provide efficient, fully integrated and accurate speech solutions for periodontal charting, clinical notes and more. With Bola AI, practices can empower themselves to create a smarter patient experience while improving operational efficiency and driving revenue. Get ready to revolutionize the way your practice operates with Bola AI. Bola AI is headquartered in Boston, MA. For more information, visit bola.ai.

About Overjet

Founded by experts from MIT and the Harvard School of Dental Medicine, Overjet develops accurate and quantified ways to detect pathologies and integrates actionable insights into workflows. Every day, private practices, dental groups and insurance companies rely on the accurate information provided by Overjet to drive care and service to patients. Learn more at overjet.ai.

Share article on social media or email:

Boyd Industries Acquires the Global Surgical SMR Product Line and Now…


Odontogenic sinusitis is fairly common, yet it is prone to misdiagnosis. ODS is uniquely suited to both dental and ENT specialties. A collaborative approach between otolaryngologists and dental…

(PRWeb March 07, 2023)

Read the full story at https://www.prweb.com/releases/boyd_industries_acquires_the_global_surgical_smr_product_line_and_now_caters_to_dental_and_ent_specialists/prweb19209154.htm

Oshi Health Appoints Randy Forman as Chief Commercial Officer and Ryan Powers as Chief Financial Officer


Oshi Health logo

Oshi Health delivers virtual multidisciplinary digestive care that patients love

“Being at the fulcrum of category transformation never gets old, and I can’t wait to help Oshi Health scale the impact of its much needed care to support the larger healthcare transformation towards preventive care,” said Randy Forman, Chief Commercial Officer of Oshi Health.

Oshi Health, the virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced that two digital health veterans have joined its leadership team: Randy Forman as Chief Commercial Officer and Ryan Powers as Chief Financial Officer. Both have fueled high velocity growth for digital health leaders.     

Riding the momentum from a groundbreaking clinical study that’s fueling innovative contracts with national health plans for Oshi Health, Forman and Powers will play influential roles in the company’s next phase of growth, helping to scale its clinical team nationwide and forging relationships with health plans, employers, channel partners, and provider groups.

Forman was the first commercial employee at Livongo, the digital health pioneer that transformed chronic disease outcomes by combining data and care protocols. There, he created and led the company’s commercial strategy, delivering value across multiple sectors. He has done the same in musculoskeletal care with Vida Health and most recently in mental health with Path.

“This is a pivotal moment for digestive healthcare as the true magnitude of the problem is just becoming clear, a shift towards behavioral treatments emphasizing the mind-gut connection gains traction, and the industry confronts systemic issues like a lack of access and worsening physician shortages,” said Forman. “Being at the fulcrum of category transformation never gets old, and I can’t wait to help Oshi Health scale the impact of its much needed care to support the larger healthcare transformation towards preventive care.”

Powers joins Oshi from NOCD, the digital behavioral health company that he helped grow from 30 to 300 employees in 2 years. Combining finance, strategy and operational lenses, he is uniquely experienced in scaling clinical workforces and operations while instilling quality and preserving culture.

“Oshi Health is building a clinical workforce that could only exist in a virtual care model and redefining the experience of care for patients as well as clinicians,” said Powers. “Its proven clinical outcomes, committed focus, growing network of partners and authentic culture all make it an early market leader in this new era of hybrid collaborative care. I’m thrilled to help Oshi grow and improve the quality of care for all digestive health sufferers.”

“We’ve paved the way for broad access to proven treatments that have not previously been properly supported or incentivized in traditional care while building value for patients, employers, health plans and provider groups,” said Sam Holliday, Oshi Health CEO. “Moments like this are rare – we’re seeing all stakeholders waking up to the urgency of digitally enabled digestive care and Randy and Ryan will ensure that we scale in all of the right ways.”

Oshi Health’s virtual multidisciplinary digestive care model is transforming access and outcomes through high-touch, evidence-based, whole-person care — including often-neglected dietary and psychosocial interventions – as a covered benefit.

About Oshi Health

Oshi Health is a completely redesigned digestive health care experience that transforms access to care, the patient experience, clinical outcomes and healthcare economics. In a high-touch virtual care delivery model, Oshi Health provides diagnosis and integrated care for digestive conditions and empowers people to achieve lasting control of their symptoms. Launched in 2020, Oshi Health works with innovative employers, health insurance partners, health systems and community GI practices to scale access to multidisciplinary care, reduce healthcare costs, and improve the lives of millions of Americans with chronic gastrointestinal diseases. For more information, visit http://www.oshihealth.com.

Share article on social media or email:

Exploring Accessibility in Rare Disease Clinical Research, 4-Day Webinar Series Hosted by Xtalks


Will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.

Each panel in this 4-day webinar series, whether watched individually or in totality with the other panels, will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.

Panel 1: Is Disability Part of Your DEI Planning and Engagement in Rare Disease?

Time: Monday, March 27, 2023, from 10am – 11am EDT

Moderator: Kendall Davis, Director, Advocacy Strategy, Centre for Rare Diseases, ICON plc

Panelists: Erika Heiges, MPH, CHES, Senior Engagement Strategy Lead, Clinical Trial Engagement & Enrollment & DAWN DDiCT Team Lead, Bristol Myers Squibb; James Huang, MD, Director of Student Health Services, Gallaudet University; Amir Rahimi, Senior Manager, Product Communications and Public Affairs, Janssen Pharmaceuticals; Angela Rochelle, Head of Healthcare Diversity Initiatives, Langland; and Grayson Schultz, Writer, Activist and Educator.

Panel 2: Unique Considerations Around Accessibility for Global Clinical Trials Time: Monday, March 27, 2023, from 11am – 12pm EDT

Moderator: Bojana Mirosavljevic, MSc, Director, Patient Advocacy Strategy, ICON plc

Panelists: Nikhil Jayswal, Director, IBD Patient Support Foundation (India); Svenja Kaden, PhD, Vice President, SCN2A Germany e.V.; and Andres Trevino, Patient Advocacy, Chiesi Global Rare Diseases.

Panel 3: Not All Measures Matter: How to Identify Outcomes Measures Appropriate for Your Rare Disease Patient Populations

Time: Tuesday, March 28, 2023, from 10am – 11am EDT

Moderator: Devra Densmore, MPA, Principal Consultant, Elevate Advocacy

Panelists: Gabrielle Conecker, MPH, Executive Director and Co-Founder, Decoding Developmental Epilepsies; Nasha Fitter, MBA, Cofounder and CEO, FOXG1 Research Foundation and VP, Patient Network & Data, Invitae; Tjitske Kleefstra, PhD, Professor, Radboudumc Nijmegen and ErasmusMC, Rotterdam, The Netherlands; Pat Koochaki, PhD, Principal, Patient Centered Outcomes, ICON plc; and Tanja Zdolšek Draksler, PhD, Researcher and Project Manager, Jožef Stefan Institute & Founder and leader, IDefine Europe.

Panel 4: Best Practices in Accessible Clinical Trial Design

Time: Wednesday, March 29, 2023, from 10am – 11am EDT

Moderator: Patti Murphy, Sr. Director of Therapeutic Expertise, ICON plc

Panelists: Rigoberto “Rigo” Garcia, Executive Director, Hemophilia Foundation of Southern California; Veronica Moore, Senior Manager, Patient Advocacy, Horizon Therapeutics; Zo Ratnasi, President & Master Strategist, sixsense strategy group; and Tricha Shivas, Chief Strategy Officer, Foundation for Sarcoidosis Research (FSR).

Panel 5: Accessibility in Rare Disease Paediatric Clinical Trials

Time: Wednesday, March 29, 2023, from 11am – 12pm EDT

Moderator: Firas Taha, MD, Medical Director, Neurology, Medical Affairs, ICON plc

Panelists: Jana Banesh, Director of Therapeutic Expertise, ICON plc; Sarita Edwards, CEO & President, The E.WE Foundation; and Ryan Sheedy, Dad, Rare Disease Caregiver & Founder, mejo.

Panel 6: Where do Expanded Access Programs fit into Trial Accessibility?

Time: Thursday, March 30, 2023, from 10am – 11am EDT

Moderator: Will Maier, Vice President, Center for Rare Diseases, ICON plc

Panelists: Deborah Gelinas, MD, Executive Director, Neuromuscular, argenx; Jack Johnson, Executive Director & Cofounder, Fabry Support & Information Group; and Ray Kaczmarek, Senior Director, Project Operations, Commercialisation & Outcomes, ICON plc.

Panel 7: Meeting Trial Participants Where They’re at: Where DCTs can help Achieve Greater Accessibility

Time: Thursday, March 30, 2023, from 11am – 12pm EDT

Moderator: Afshawn Chakamian, Director of Therapeutic Expertise, ICON plc

Panelists: Ashmee Bharadia, BSc (Hons), Vice President, In Home Services, Accellacare; Sneha Dave, Executive Director, Generation Patient; Craig Lipset, Co-Chair, Decentralized Trials & Research Alliance, Adjunct Assistant Professor, Rutgers University, Vice President, Foundation for Sarcoidosis Research, Managing Partner, Clinical Innovation Partners; and Katie Wright, Person living with VEDS; Host of Staying Connected podcast.

For more information, or to register for this 4-day series starting on Monday, March 27, 2023, visit Rare Disease Week 2023: Exploring Accessibility in Rare Disease Clinical Research.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com